NASDAQ:GBIO Generation Bio - GBIO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Generation Bio Co. Please log in to your account or sign up in order to add this asset to your watchlist. $3.88 -0.02 (-0.51%) (As of 03/22/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.78▼$4.0050-Day Range$3.61▼$7.0152-Week Range$3.40▼$9.59Volume187,353 shsAverage Volume225,503 shsMarket Capitalization$231.52 millionP/E RatioN/ADividend YieldN/APrice Target$12.31 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Generation Bio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside217.2% Upside$12.31 Price TargetShort InterestBearish2.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$24,514 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.14) to ($1.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.36 out of 5 starsMedical Sector238th out of 986 stocksPharmaceutical Preparations Industry100th out of 477 stocks 3.5 Analyst's Opinion Consensus RatingGeneration Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.31, Generation Bio has a forecasted upside of 217.2% from its current price of $3.88.Amount of Analyst CoverageGeneration Bio has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.69% of the float of Generation Bio has been sold short.Short Interest Ratio / Days to CoverGeneration Bio has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Generation Bio has recently increased by 0.78%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGeneration Bio does not currently pay a dividend.Dividend GrowthGeneration Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GBIO. Previous Next 2.1 News and Social Media Coverage News SentimentGeneration Bio has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Generation Bio this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for GBIO on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Generation Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,514.00 in company stock.Percentage Held by Insiders20.70% of the stock of Generation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.09% of the stock of Generation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Generation Bio are expected to grow in the coming year, from ($2.14) to ($1.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Generation Bio is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Generation Bio is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeneration Bio has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Generation Bio (NASDAQ:GBIO) StockGeneration Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Read More Receive GBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Generation Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GBIO Stock News HeadlinesMarch 21, 2023 | finance.yahoo.comGeneration Bio to Participate in the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic MedicinesFebruary 27, 2023 | finance.yahoo.comGeneration Bio to Present at the 43rd Annual Cowen Healthcare ConferenceMarch 23, 2023 | Upexi, Inc (Ad)Could This Be The Biggest Stock Of 2023?This Little Known Company Has Been Growing It's Revenue By Over 100% Year Over Year!February 24, 2023 | markets.businessinsider.comNeedham Keeps Their Buy Rating on Generation Bio (GBIO)February 24, 2023 | finance.yahoo.comBullish insiders bet US$536k on Generation Bio Co. (NASDAQ:GBIO)February 23, 2023 | finance.yahoo.comGeneration Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial ResultsFebruary 19, 2023 | nypost.comNew Gen Z workers already burned out and disconnectedFebruary 10, 2023 | msn.comGen. Milley Has Long Combat History, Contrary to Social Media PostsMarch 23, 2023 | Upexi, Inc (Ad)The Stock That Is Flying Under Wall St. RadarWith The Founder OF XPO Logistics Leading The Way This Nasdaq Company is Ready and GOING!January 23, 2023 | nypost.comFrugal Gen Z fashionistas are bringing back ‘easy’ 1990s grunge looksJanuary 3, 2023 | finance.yahoo.comGeneration Bio to Present at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2023 | marketwatch.comHow and Where the Next Generation Sequencing (NGS) Market is Set to Grow in forecast period 2028December 21, 2022 | marketwatch.comNext Generation Biofuel Market (New Report) 2023 To Garner Overwhelming Hike In Revenues by 2028 | 80 Pages ReportDecember 5, 2022 | finance.yahoo.comCan Generation Bio Co. (GBIO) Climb 184% to Reach the Level Wall Street Analysts Expect?November 18, 2022 | finance.yahoo.comWall Street Analysts Think Generation Bio Co. (GBIO) Could Surge 176%: Read This Before Placing a BetNovember 4, 2022 | finance.yahoo.comGeneration Bio Reports Business Highlights and Third Quarter 2022 Financial ResultsNovember 1, 2022 | finance.yahoo.comWe're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash WiselyOctober 16, 2022 | cnet.comFossil Gen 6 Wellness Edition Is the Next Wear OS 3 SmartwatchSeptember 22, 2022 | finance.yahoo.comGeneration Bio to Present at the 2022 Jefferies Cell and Genetic Medicine SummitSeptember 20, 2022 | finance.yahoo.comGeneration Bio Names Phillip Samayoa, Ph.D. Chief Strategy OfficerSeptember 19, 2022 | nasdaq.comInsider Buying: The Generation Bio Co. (NASDAQ:GBIO) Independent Director Just Bought 24% More SharesSeptember 17, 2022 | finance.yahoo.comA number of insiders bought Generation Bio Co. (NASDAQ:GBIO) stock last year, which is great news for shareholdersSeptember 16, 2022 | seekingalpha.comGBIO Generation Bio Co.September 13, 2022 | msn.comLatAm’s Gen-t is working to enrich biotech with Brazilian genomic dataAugust 4, 2022 | finance.yahoo.comGeneration Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue EstimatesAugust 4, 2022 | apnews.comGeneration Bio Reports Business Highlights and Second Quarter 2022 Financial ResultsAugust 4, 2022 | finance.yahoo.comGeneration Bio Reports Business Highlights and Second Quarter 2022 Financial ResultsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Generation Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GBIO Company Calendar Last Earnings11/10/2021Today3/22/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GBIO CUSIPN/A CIK1733294 Webgenerationbio.com Phone617-655-7500FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.31 High Stock Price Forecast$24.00 Low Stock Price Forecast$2.23 Forecasted Upside/Downside+217.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-136,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-43.07% Return on Assets-33.28% Debt Debt-to-Equity RatioN/A Current Ratio14.99 Quick Ratio14.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.75 per share Price / Book0.82Miscellaneous Outstanding Shares59,670,000Free Float47,315,000Market Cap$231.52 million OptionableNot Optionable Beta1.95 Key ExecutivesDr. Cameron Geoffrey McDonough M.D. (Age 53)Pres, CEO, Sec. & Director Comp: $935.37kDr. Matthew Norkunas M.B.A. (Age 45)M.D., Chief Financial Officer Comp: $604.16kDr. Matthew Stanton Ph.D. (Age 50)Chief Scientific Officer Comp: $647.42kDr. Douglas Kerr M.B.A. (Age 56)M.D., Ph.D., Chief Medical Officer Comp: $651.64kDr. Tracy Zimmermann Ph.D. (Age 53)Chief Devel. Officer Comp: $590.56kDr. Mark D. Angelino Ph.D. (Age 50)Co-Founder Dr. Robert Kotin Ph.D. (Age 67)Co-Founder & Advisor Ms. Antionette Paone M.B.A. (Age 45)M.S., Chief Operating Officer Dr. Jennifer Elliott Esq.J.D., Ph.D., Chief Legal OfficerDr. Phillip Samayoa Ph.D.Chief Strategy OfficerMore ExecutivesKey CompetitorsNektar TherapeuticsNASDAQ:NKTRSelecta BiosciencesNASDAQ:SELBRain OncologyNASDAQ:RAINALX OncologyNASDAQ:ALXOAnnexonNASDAQ:ANNXView All CompetitorsInsiders & InstitutionsAlliancebernstein L.P.Bought 3,900 shares on 2/16/2023Ownership: 0.096%Morgan StanleyBought 5,092 shares on 2/15/2023Ownership: 0.828%State of Wisconsin Investment BoardSold 6,745 shares on 2/15/2023Ownership: 0.207%Millennium Management LLCBought 15,571 shares on 2/15/2023Ownership: 0.044%Public Employees Retirement System of OhioSold 2,497 shares on 2/15/2023Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions GBIO Stock - Frequently Asked Questions Should I buy or sell Generation Bio stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Generation Bio in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GBIO shares. View GBIO analyst ratings or view top-rated stocks. What is Generation Bio's stock price forecast for 2023? 5 Wall Street analysts have issued 12 month price targets for Generation Bio's stock. Their GBIO share price forecasts range from $2.23 to $24.00. On average, they anticipate the company's stock price to reach $12.31 in the next twelve months. This suggests a possible upside of 217.2% from the stock's current price. View analysts price targets for GBIO or view top-rated stocks among Wall Street analysts. How have GBIO shares performed in 2023? Generation Bio's stock was trading at $3.93 at the beginning of the year. Since then, GBIO shares have decreased by 1.3% and is now trading at $3.88. View the best growth stocks for 2023 here. When is Generation Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our GBIO earnings forecast. How were Generation Bio's earnings last quarter? Generation Bio Co. (NASDAQ:GBIO) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.54) by $0.02. What ETF holds Generation Bio's stock ? Fidelity Blue Chip Growth ETF holds 849 shares of GBIO stock, representing 0.00% of its portfolio. What other stocks do shareholders of Generation Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Generation Bio investors own include DocuSign (DOCU), NVIDIA (NVDA), Overstock.com (OSTK), Boeing (BA), Pure Storage (PSTG), Mastercard (MA), QUALCOMM (QCOM), Riot Platforms (RIOT), Twilio (TWLO) and Enphase Energy (ENPH). When did Generation Bio IPO? (GBIO) raised $126 million in an IPO on Friday, June 12th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Generation Bio's stock symbol? Generation Bio trades on the NASDAQ under the ticker symbol "GBIO." Who are Generation Bio's major shareholders? Generation Bio's stock is owned by a number of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (12.22%), T. Rowe Price Investment Management Inc. (6.02%), Geode Capital Management LLC (1.46%), Bank of America Corp DE (1.46%), Morgan Stanley (0.83%) and JPMorgan Chase & Co. (0.78%). Insiders that own company stock include Antoinette Paone, Charles A Rowland Jr, Donald William Nicholson, Douglas Kerr, Evan Spiegel, Geoff Mcdonough, James E Flynn, Jason P Rhodes, Matthew Stanton, Phillip Samayoa and Venture Associates X L Atlas. View institutional ownership trends. How do I buy shares of Generation Bio? Shares of GBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Generation Bio's stock price today? One share of GBIO stock can currently be purchased for approximately $3.88. How much money does Generation Bio make? Generation Bio (NASDAQ:GBIO) has a market capitalization of $231.52 million. The company earns $-136,640,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis. How many employees does Generation Bio have? The company employs 150 workers across the globe. How can I contact Generation Bio? Generation Bio's mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is generationbio.com. The company can be reached via phone at 617-655-7500 or via email at investors@generationbio.com. This page (NASDAQ:GBIO) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.